Metabolic Liver Disease: The Silent Epidemic Threatening 1.8 Billion People

Metabolic liver disease is projected to affect 1.8 billion people worldwide by 2050, according to a study published in the Lancet Gastroenterology & Hepatology journal. The research suggests that the condition is reaching epidemic proportions, driven primarily by rising global rates of obesity and blood sugar levels.

The condition is known as metabolic dysfunction-associated steatotic liver disease, or MASLD. This term serves as an umbrella for liver conditions that develop in the presence of one or more cardiometabolic risk factors, such as high blood sugar.

MASLD was previously referred to as non-alcoholic fatty liver disease (NAFLD). It is currently identified as one of the most prevalent and rapidly growing liver conditions on a global scale.

Current Prevalence and Growth

Latest estimates indicate that 1.3 billion people worldwide are currently living with MASLD. This represents a 143 per cent increase in prevalence over the last three decades.

The data, derived from the global burden of diseases, injuries, and risk factors study (GBD), suggests that approximately 16 per cent of the global population—or one in six people—is affected by the disease.

Risk Factors and Drivers

The surge in metabolic liver disease is closely linked to modern lifestyle factors and metabolic disorders. Key drivers include high sugar intake, obesity, and the consumption of ultra-processed foods, all of which can lead to the accumulation of fat in the liver.

Beyond diet, other contributors to the development of MASLD include:

• Diabetes and insulin resistance
• High cholesterol
• Poor sleep patterns
• Environmental factors
• Unregulated use of over-the-counter medications, which can cause toxin build-up and damage healthy liver tissue

These factors disrupt metabolic balance and trigger the onset of liver dysfunction, even in individuals who do not consume alcohol.

Regional Impact and Clinical Progression

The impact of liver disease is becoming a significant concern in specific regions. In India, data from the Indian Council of Medical Research indicates that nearly 40 per cent of the population will experience a disease related to the liver during their lifetime.

Medical professionals describe this as a silent disease because liver damage can occur without obvious symptoms in its early stages. However, if left unchecked, the metabolic dysfunction can progress to more severe conditions, including cirrhosis and liver cancer.

The liver serves as a vital organ responsible for metabolism, digestion, and detoxification. When fat accumulates due to the aforementioned risk factors, it triggers the progression of MASLD, which can eventually compromise these essential functions.